Renalytix to Report Financial Results for Third Quarter Fiscal 2022 on June 30

Rhea-AI Summary

Renalytix plc (NASDAQ: RNLX) will report its third quarter fiscal 2022 financial results on June 30, 2022, before market open. The company plans to hold a conference call at 8:30 a.m. ET to discuss these results and outline business strategy, partnerships, and regulatory matters. Interested participants can join via dial-in numbers or the provided webcast link. Renalytix is at the forefront of bioprognosis for kidney health, with its lead product, KidneyIntelX™, receiving Breakthrough Designation from the FDA.

NEW YORK and SALT LAKE CITY, June 23, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will report its third quarter fiscal 2022 financial results on Thursday, June 30, 2022, before market open. The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. (ET) / 1:30 p.m. (GMT).

Conference Call Details:
US/Canada Participant Toll-Free Dial-In Number: (833) 614-1551
US/Canada Participant International Dial-In Number: (914) 987-7290
United Kingdom International Dial-In Number: 0800 0288 438
United Kingdom Local Dial-In Number: 0203 1070 289
Conference ID: 1546327

Webcast Registration link:  https://edge.media-server.com/mmc/p/y3zwhkuk

For further information, please contact:
Renalytix plc	www.renalytix.com
James McCullough, CEO	Via Walbrook PR
Stifel (Nominated Adviser, Joint Broker)	Tel: 020 7710 7600
Alex Price / Nicholas Moore
Investec Bank plc (Joint Broker)	Tel: 020 7597 4000
Gary Clarence / Daniel Adams
Walbrook PR Limited	Tel: 020 7933 8780 or renalytix@walbrookpr.com
Paul McManus / Lianne Applegarth / Alice Woodings	Mob: 07980 541 893 / 07584 391 303 / 07407 804 654
CapComm Partners	Tel: 415-389-6400 or investors@renalytix.com
Peter DeNardo

About Renalytix
Renalytix (LSE: RENX) (NASDAQ: RNLX) is the global founder and leader in the new field of bioprognosis™ for kidney health. The company has engineered a new solution that enables early-stage chronic kidney disease progression risk assessment. The Company’s lead product, KidneyIntelX™, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com). For more information, visit www.renalytix.com. 

FAQ

When will Renalytix report its Q3 2022 financial results?

Renalytix will report its third quarter fiscal 2022 financial results on June 30, 2022.

What time is the Renalytix conference call?

The conference call for Renalytix is scheduled for 8:30 a.m. ET on June 30, 2022.

How can I listen to Renalytix's Q3 financial results call?

You can listen to the call via the US/Canada toll-free number (833) 614-1551 or register for the webcast through the provided link.

What is Renalytix's lead product?

Renalytix's lead product is KidneyIntelX™, designed for assessing the risk of chronic kidney disease progression.

What designation has KidneyIntelX™ received?

KidneyIntelX™ has been granted Breakthrough Designation by the U.S. FDA.